Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to evaluate the molecular features of clear cell adenocarcinoma (CCA) of the urinary tract and investigate its pathogenic pathways and possible actionable targets.Materials and Methods We retrospectively collected the data of patients with CCA between January 1999 and December 2016; the data were independently reviewed by two pathologists. We selected five cases of urinary CCA, based on the clinicopathological features. We analyzed these five cases by whole exome sequencing (WES) and subsequent bioinformatics analyses to determine the mutational spectrum and possible pathogenic pathways.Results All patients were female with a median age of 62 years. All tumors were located in the urethra and showed aggressive behavior with disease progression. WES revealed several genetic alterations, including driver gene mutations (<i>AMER1, ARID1A, CHD4, KMT2D, KRAS, PBRM1</i>, and <i>PIK3R1</i>) and mutations in other important genes with tumor-suppressive and oncogenic roles (<i>CSMD3, KEAP1, SMARCA4</i>, and <i>CACNA1D</i>). We suggest putative pathogenic pathways (chromatin remodeling pathway, mitogen-activated protein kinase signaling pathway, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Wnt/β-catenin pathway) as candidates for targeted therapies.Conclusion Our findings shed light on the molecular background of this extremely rare tumor with poor prognosis and can help improve treatment options.
Abstract
Purpose This study aimed to evaluate the molecular features of clear cell adenocarcinoma (CCA) of the urinary tract and investigate its pathogenic pathways and possible actionable targets. Materials and Methods We retrospectively collected the data of patients with CCA between January 1999 and December 2016; the data were independently reviewed by two pathologists. We selected five cases of urinary CCA, based on the clinicopathological features. We analyzed these five cases by whole exome sequencing (WES) and subsequent bioinformatics analyses to determine the mutational spectrum and possible pathogenic pathways. Results All patients were female with a median age of 62 years. All tumors were located in the urethra and showed aggressive behavior with disease progression. WES revealed several genetic alterations, including driver gene mutations (AMER1, ARID1A, CHD4, KMT2D, KRAS, PBRM1, and PIK3R1) and mutations in other important genes with tumor-suppressive and oncogenic roles (CSMD3, KEAP1, SMARCA4, and CACNA1D). We suggest putative pathogenic pathways (chromatin remodeling pathway, mitogen-activated protein kinase signaling pathway, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Wnt/β-catenin pathway) as candidates for targeted therapies. Conclusion Our findings shed light on the molecular background of this extremely rare tumor with poor prognosis and can help improve treatment options.
참고문헌 (30)
- Netto GJ, "The 2022 World Health Organization classifica tion of tumors of the urinary system and male genital organs part B : prostate and urinary tract tumors", Eur Urol, 82, pp.469~482 (2022)
- Venyo AK, "Clear cell adenocarcinoma of the urethra : review of the literature", Int J Surg Oncol, 2015, pp.790235~ (2015)
- Alexiev BA, "Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra : histogenesis and diagnostic problems", Virchows Arch, 462, pp.193~201 (2013)
- Tong GX, "Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract : evidence of related histogenesis?", Am J Surg Pathol, 32, pp.1380~1387 (2008)
- Sung MT, "Histogenesis of clear cell adenocarci noma in the urinary tract : evidence of urothelial origin", Clin Cancer Res, 14, pp.1947~1955 (2008)
- Ortiz-Bruchle N, "Molecular characterization of Muelle rian tumors of the urinary tract", Genes(Basel), 12, pp.880~ (2021)
- Lin CY, "Molecular profiling of clear cell adenocarcinoma of the urinary tract", Virchows Arch, 475, pp.727~734 (2019)
- Mehra R, "Primary urethral clear-cell adenocarcinoma : comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing", Am J Pathol, 184, pp.584~591 (2014)
- Tate JG, "COSMIC : the Catalogue Of Somatic Mutations In Can cer", Nucleic Acids Res, 47, pp.D941~D947 (2019)
- Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
- Ashburner M, "Gene ontology : tool for the unification of biology. The Gene Ontology Consortium", Nat Genet, 25, pp.25~29 (2000)
- Grosser D, "Clear cell adenocarcinoma in men : a series of 15 cases", Am J Surg Pathol, 45, pp.270~276 (2021)
- Patel M, "The epidemiology and role of surgery in the treatment of urethral clear cell car cinoma", Int Urol Nephrol, 52, pp.51~57 (2020)
- Ding L, "Somatic mutations affect key pathways in lung adenocarcinoma", Nature, 455, pp.1069~1075 (2008)
- Paner GP, "Mesonephric(Wolffi an-derived)adenocarcinoma of the female urethra", Am J Surg Pathol, 45, pp.543~549 (2021)
- Gunes C, "Implications of TERT promoter mutations and telomerase activity in urothelial car cinogenesis", Nat Rev Urol, 15, pp.386~393 (2018)
- AACR Project GENIE Consortium, "AACR Project GENIE : Powering Precision Medicine through an International Con sortium", Cancer Discov, 7, pp.818~831 (2017)
- Saliani M, "From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers", Cancer Biol Med, 16, pp.435~461 (2019)
- Tanneberger K, "Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1(Amer1)", J Biol Chem, 286, pp.19204~19214 (2011)
- Oh YS, "Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling", Int J Mol Sci, 19, pp.26~ (2017)
- Taguchi K, "The KEAP1-NRF2 system in cancer", Front Oncol, 7, pp.85~ (2017)
- Vanhaesebroeck B, "The emerging mechanisms of isoform-specific PI3K signalling", Nat Rev Mol Cell Biol, 11, pp.329~341 (2010)
- Wilson BG, "SWI", SNF nucleosome remodellers and cancer, 2011, pp.11, 481~492
- Gad S, "Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway", Oncol Lett, 22, pp.835~ (2021)
- Yap TA, "Phase I trial of first-in-class ATR in hibitor M6620(VX-970)as monotherapy or in combination with carboplatin in patients with advanced solid tumors", J Clin Oncol, 38, pp.3195~3204 (2020)
- Banerjee S, "ATARI trial : ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss(ENGOT", GYN1, Int J Gynecol Cancer, pp.2021, 31[DOI]
- Qi W, "Acetyltrans ferase p300 collaborates with chromodomain helicase DNA binding protein 4(CHD4)to facilitate DNA double-strand break repair", Mutagenesis, 31, pp.193~203 (2016)
- Froimchuk E, "Histone H3 lysine 4 methyltrans ferase KMT2D", Gene, 627, pp.337~342 (2017)
- Wiegand KC, "ARID1A mutations in endometriosis-associated ovarian carcinomas", N Engl J Med, 363, pp.1532~1543 (2010)
- Wang L, "Immunohistochemistry and next-generation sequ encing are complementary tests in identifying PTEN abnor mality in endometrial carcinoma biopsies", Int J Gynecol Pathol, 41, pp.12~19 (2022)